65085-01-0

Basic information

• Product Name: Cefmenoxime
• Synonyms: CEFMENOXIME;(6r-(6alpha,7beta(z)))-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6α,7β(Z)]]-;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-;AB 50912;SCE 1365;[6R-[6α，7β(Z)]]-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-y1)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oet-2-ene-2-carboxylic acid;(6R,7R)-7-[[(Z)-(2-Aminothiazol-4-yl)(methoxyimino)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• CAS NO: 65085-01-0
• Molecular Formula: C16H17N9O5S3
• Molecular Weight: 511.56
• EINECS: 278-299-4
• Product Categories: Pharmaceutical intermediate
• Mol File: 65085-01-0.mol

Chemical Properties

• Appearance: White or light yellow crystalline powder, odourless
• Density: 1.96 g/cm³
• PKA: 2.61±0.50(Predicted)
• CAS DataBase Reference: Cefmenoxime(CAS DataBase Reference)
• NIST Chemistry Reference: Cefmenoxime(65085-01-0)
• EPA Substance Registry System: Cefmenoxime(65085-01-0)

Safety Data

• Hazardous Substances Data: 65085-01-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cefmenoxime is used as an antibiotic for treating bacterial infections. It is particularly effective against a wide range of gram-negative and some gram-positive bacteria, making it a valuable asset in the fight against various infections.
Used in Organic Synthesis:
In addition to its pharmaceutical applications, Cefmenoxime is also utilized as a compound in organic synthesis. Its unique chemical structure allows it to be a useful building block for the development of other complex molecules and pharmaceuticals, further expanding its utility in the chemical and pharmaceutical industries.

Originator

Tacef,Takeda,W. Germany,1983

Manufacturing Process

7β-[α-Methoxyimino-α-(2-aminothiazol-4-yl)acetamido]cephalosporanicacid trifluoroacetic acid salt is dissolved in a solution of 272 mg of 1-methyl-5- mercapto-1H-tetrazole, 555 mg of sodium bicarbonate and 68 mg of triethylbenzylammonium bromide in 10 ml of water. The solution is heated at 60°C in nitrogen atmosphere for 6 hours. After cooling, the reaction solution is passed through a column of Amberlite XAD-2 and eluted with water and then with 2.5% ethanol. The procedure yields sodium 7β-[α-methoxyimino-α- (2-aminothiazol-4-yl)acetamido]-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-3- cephem-4-carboxylate, MP 174°C to 175°C (decomposition).

Therapeutic Function

Antibacterial

Antimicrobial activity

A semisynthetic cephalosporin supplied as the hydrochloride. Its activity is very similar to that of cefotaxime. A 500 mg intramuscular injection achieves a plasma concentration of 15 mg/L after 40 min. A concentration of 200 mg/L is attained after intravenous administration of 1 g. The plasma half-life is c. 1 h. Around 77% is protein bound. Probenecid increases peak plasma levels and extends the plasma half-life to 1.8 h. Therapeutic concentrations are achieved in CSF. There is a degradation product with a long half-life (around 40 h), but 80–92% of the drug is recovered unchanged from the urine. In patients with renal insufficiency, no significant relation was found between creatinine clearance and peak serum concentrations but there was a linear relationship with plasma half-life and total body clearance. About 10% of the dose appears in the feces, mostly extensively degraded, possibly by the fecal flora. Toxicity, side effects and clinical use are those common to group 4 cephalosporins.

InChI:InChI=1/C16H17N9O5S3/c1-24-16(20-22-23-24)32-5-6-4-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-3-18-15(17)33-7/h3,9,13H,4-5H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8+/t9-,13-/m1/s1

Upstream product

• 24209-38-9 3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 179258-53-8 4-(diethylphosphoryl)-2-(2-amino-4-thiazolyl)-2-syn-(2-methoxyimino)acetate 
• 65872-41-5 cefotaxime 
• 65243-35-8 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester 
• 24209-38-9 (6R,7R)-7-amino-3-[(1H-1-methyltetrazol-5-yl)thio]methylceph-3-em-4-carboxylic acid 
• 207725-19-7 (2-Amino-thiazol-4-yl)-[(Z)-methoxyimino]-acetic acid 4,6-dimethoxy-[1,3,5]triazin-2-yl ester 

Relevant articles and documents

NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES

A novel 4-halo-2-oxyimino-3-oxo butyric acid-N, N-dimethyl formiminium chloride chlorosulfate of formula (I) useful in the preparation of cephalosporin antibiotics, wherein X is chlorine or bromine; R is hydrogen, C1-4 alkyl group, an easily removable hydroxyl protective group, -CH2COOR5, or -C(CH3)2COOR5, wherein R5 is hydrogen or an easily hydrolysable ester group. The compound of formula (I) is prepared by reacting 4-halo-2-oxyimino-3-oxobutyric acid of formula (IV1), wherein X, R and R5 are as defined above, with N, N-dimethylformiminium chloride chlorosulphate of formula (VII), in an organic solvent at a temperature ranging from -30 °C to -15 °C. The cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, cefquinome, ceftazidime, cefteram pivoxil, ceftiofur, ceftizoxime, ceftriaxone and cefuzonam.

Method for producing cephalosporins

A method for producing cephalosporins 7-substituted with an amino-thiazolylacetic group by reacting 7-ACA or its derivatives having the amino group and the carboxyl protected with reactive derivatives of amino-thiazolylacetic acid.

2-chloro-4,6-dimethoxy-1,3,5-triazine: A new effective and convenient coupling reagent for cephalosporin derivatives

Chloro-4,6-dimethoxy-1,3,5-triazine(CDMT) 2 was reacted with 2-(2- amino-4-thiazolyl)-2-syn-alkoxyiminoacetic acid 1 to give an active ester intermediate 3.

Diethyl chlorophosphate: An effective and convenient coupling reagent of cephalosporin derivatives

A coupling reagent, diethyl chlorophosphate (DECP) 2, was reacted with 2-(2-amino-4-thiazolyl)-2-syn-alkoxyiminoacetic acid 1 to give an active ester intermediate 3.

Alkyloximes of 7-amino-thiazolyl-acetamido-cephalosporanic acids

Novel alkyloximes of 7-amino-thiazolyl-acetamidocephalosporanic acids of the formula STR1 wherein R is selected from the group consisting of alkyl of 1 to 5 carbon atoms, cycloalkyl of 3 to 5 carbon atoms and --CH2 --SR', R' is selected from the group consisting of acyl of an alkanoic acid of 2 to 4 carbon atoms, 1-methyl-tetrazolyl and 2-methyl-1,3,4-thiadiazolyl, R1 is selected from the group consisting of hydrogen and a group easily removeable by acid hydrolysis or hydrogenolysis, R2 is selected from the group consisting of alkyl of 1 to 4 carbon atoms and alkenyl and alkynyl of 2 to 4 carbon atoms, A is selected from the group consisting of hydrogen, an alkali metal cation, an equivalent of an alkaline earth metal or magnesium, an organic amine base cation and an ester group easily removeable by acid hydrolysis or hydrogenolysis with the proviso that when R1 is hydrogen, A is not an ester group easily removeable by hydrogenolysis or acid hydrolysis and the wavy line means that OR2 is in one or the other of the two possible syn or anti isomeric positions having a very good antibiotic activity and novel processes and intermediates for their preparation.